The global NGS-based RNA-Sequencing Market is witnessing rapid growth, driven by advancements in genomics, increasing demand for precision medicine, and expanding applications in research and diagnostics. According to the latest report by Straits Research, the market was valued at USD 3.64 billion in 2024 and is projected to grow from USD 4.26 billion in 2025 to USD 14.95 billion by 2033, expanding at a compound annual growth rate (CAGR) of 17% during the forecast period (2025–2033).

NGS-based RNA sequencing (RNA-Seq) is a powerful technology used to analyze the transcriptome, providing insights into gene expression, RNA structure, and molecular mechanisms of diseases. It is widely used in applications such as cancer research, drug discovery, and personalized medicine. The increasing focus on understanding genetic variations and disease pathways is significantly contributing to market expansion.

Market Dynamics

Growing Demand for Precision Medicine and Genomic Research

The rising adoption of precision medicine is a key driver of the NGS-based RNA-sequencing market. RNA-Seq enables researchers and healthcare professionals to identify gene expression patterns and develop targeted therapies tailored to individual patients.

Additionally, the increasing investment in genomic research and large-scale sequencing projects is boosting demand for advanced sequencing technologies. Governments and research institutions are focusing on understanding complex diseases, further supporting market growth.

Technological Advancements in Sequencing Platforms

Continuous advancements in next-generation sequencing (NGS) technologies are enhancing the efficiency, accuracy, and speed of RNA sequencing. Innovations such as high-throughput sequencing, improved data analysis tools, and cost-effective solutions are making RNA-Seq more accessible.

Moreover, the integration of artificial intelligence (AI) and bioinformatics is enabling better interpretation of sequencing data, facilitating faster and more accurate research outcomes. These advancements are driving the adoption of NGS-based RNA sequencing across various applications.

Download Free Sample: https://straitsresearch.com/report/ngs-based-rna-sequencing-market/request-sample

Market Segmentation

The NGS-based RNA-sequencing market is segmented based on various parameters, categorized under segmentation code 10118. These segments include products, technologies, applications, and end users, enabling companies to cater to diverse research and clinical needs.

Key segments include sequencing platforms, reagents, and services. Among these, reagents and consumables hold a significant share due to their recurring usage in sequencing workflows. The increasing demand for high-throughput sequencing solutions is further supporting market growth.

Regional Analysis

North America holds a dominant share of the global NGS-based RNA-sequencing market, driven by strong research infrastructure, high investment in biotechnology, and the presence of leading market players.

Europe is also a key market, supported by increasing government funding for genomic research, growing adoption of precision medicine, and advancements in healthcare technologies.

Asia-Pacific is expected to witness the fastest growth during the forecast period due to expanding biotechnology and pharmaceutical industries, increasing research activities, and rising healthcare investments in countries such as China, India, and Japan.

Latin America and the Middle East and Africa are emerging markets, driven by improving research infrastructure and growing awareness of advanced genomic technologies.

Competitive Landscape

The global NGS-based RNA-sequencing market is highly competitive, with key players focusing on technological innovation, strategic collaborations, and product development to strengthen their market presence. Prominent companies operating in the market include:

Illumina
Thermo Fisher Scientific
Oxford Nanopore
Agilent Technologies, Inc.
BGI
PerkinElmer Inc.
QIAGEN
Eurofins Scientific
F. Hoffmann-La Roche Ltd
Takara Bio Inc.
Tecan Genomics, Inc.

These companies are investing heavily in research and development to introduce advanced sequencing platforms, improve data analysis capabilities, and expand their product portfolios. Partnerships and acquisitions are key strategies adopted to enhance market competitiveness.

Key Trends and Opportunities

The increasing adoption of single-cell RNA sequencing is a major trend shaping the market. This technology allows researchers to study gene expression at the individual cell level, providing deeper insights into cellular functions and disease mechanisms.

Additionally, the growing use of RNA sequencing in clinical diagnostics is creating new opportunities for market growth. RNA-Seq is being increasingly used for disease detection, biomarker discovery, and treatment monitoring.

Another significant opportunity lies in the expansion of personalized medicine and targeted therapies, where RNA sequencing plays a crucial role in identifying patient-specific treatment options.

Conclusion

The global NGS-based RNA-sequencing market is poised for substantial growth, driven by advancements in genomics, increasing demand for precision medicine, and expanding research applications. With a projected market size of USD 14.95 billion by 2033 and a CAGR of 17%, the market offers significant opportunities for innovation and expansion.

As the healthcare and research sectors continue to focus on understanding complex genetic mechanisms and developing targeted therapies, the demand for NGS-based RNA sequencing technologies is expected to rise, supporting long-term market growth.